Carlos Pantojas, MD
Rheumatology · San Juan, PRNPI 1144299074
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $104 of the $144 with a category attached, or 72.0%. 5 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 52.3% of the total. Reporting peaked in 2019 at $76 and has fallen 79.8% since, to $15 in 2025. That places this record below the midpoint for rheumatology clinicians in PR, where the typical reported total is $2,108.
Across 9 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$75
- Pfizer Pharmaceuticals LLC$26
- GSK$15
- Merck$14
- Boehringer Ingelheim$13
Across 129 payments — averaging $25,127 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$2.9M
- E.r. Squibb & Sons, L.L.C.$304K
- Eli Lilly$84K
- Aurinia Pharma U.S., Inc.$402
What the payments were for
- Food & beverage$10472%
- Education$4028%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Pfizer Pharmaceuticals LLC | 2 | $26 |
| GSK | 1 | $15 |
| Merck | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$144 in reported general payments places this provider in the 5th percentile of 88 rheumatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 94 | $701,098 |
| RinvoqUpadacitinib | 101 | $651,637 |
| Humira(Cf) PenAdalimumab | 63 | $433,256 |
| ProliaDenosumab | 154 | $272,646 |
| EnbrelEtanercept | 12 | $87,106 |
| Humira(Cf)Adalimumab | 12 | $83,056 |
| ActemraTocilizumab | 20 | $67,889 |
| Gabapentin | 1,403 | $34,264 |
| Pregabalin | 817 | $33,934 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $29,647 |
| TymlosAbaloparatide | 11 | $29,410 |
| Diclofenac Potassium | 159 | $24,575 |
| Etodolac | 160 | $13,255 |
| Nabumetone | 195 | $11,955 |
| Duloxetine Hcl | 341 | $9,561 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in San Juan
- Radames Sierra ZoritaSan Juan$428K
- Oscar Soto RaicesSan Juan$352K
- Yvonne FontSan Juan$193K
- Paloma AlejandroSan Juan$33K
- Grissel RiosSan Juan$13K
- Irma Vazquez-SanabriaSan Juan$10K
- Ariana Gonzalez-MelendezSan Juan$9K
- Ricardo Gago PineroSan Juan$7K
- Maria RecurtSan Juan$6K
- Valerie Marrero PereaSan Juan$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.